Phibro Animal Health (NASDAQ:PAHC) CEO Jack Bendheim Sells 1,235 Shares of Stock

Phibro Animal Health Corporation (NASDAQ:PAHC) CEO Jack Bendheim sold 1,235 shares of the firm’s stock in a transaction on Friday, January 23rd. The stock was sold at an average price of $40.55, for a total value of $50,079.25. Following the completion of the transaction, the chief executive officer owned 15,445 shares in the company, valued at approximately $626,294.75. This trade represents a 7.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Jack Bendheim also recently made the following trade(s):

• On Thursday, January 22nd, Jack Bendheim sold 13,158 shares of Phibro Animal Health stock. The shares were sold at an average price of $41.98, for a total value of $552,372.84.
• On Wednesday, January 21st, Jack Bendheim sold 14,687 shares of Phibro Animal Health stock. The stock was sold at an average price of $41.68, for a total value of $612,154.16.
• On Thursday, January 15th, Jack Bendheim sold 2,932 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.02, for a total value of $117,338.64.
• On Wednesday, January 14th, Jack Bendheim sold 3,651 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.53, for a total transaction of $147,975.03.
• On Tuesday, January 13th, Jack Bendheim sold 7,551 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.32, for a total transaction of $304,456.32.
• On Friday, January 9th, Jack Bendheim sold 213 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.16, for a total transaction of $8,554.08.
• On Wednesday, January 7th, Jack Bendheim sold 328 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.09, for a total transaction of $13,149.52.
• On Thursday, December 11th, Jack Bendheim sold 5,752 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.93, for a total transaction of $235,429.36.
• On Tuesday, December 9th, Jack Bendheim sold 1,288 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.19, for a total value of $51,764.72.
• On Monday, December 8th, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.06, for a total value of $141,011.20.

Phibro Animal Health Stock Performance

Shares of PAHC opened at $39.52 on Wednesday. The company has a quick ratio of 1.35, a current ratio of 3.09 and a debt-to-equity ratio of 2.32. The business has a 50-day simple moving average of $39.97 and a two-hundred day simple moving average of $37.69. The stock has a market cap of $1.60 billion, a price-to-earnings ratio of 23.81, a PEG ratio of 1.12 and a beta of 0.79. Phibro Animal Health Corporation has a 52 week low of $16.16 and a 52 week high of $46.42.

Phibro Animal Health (NASDAQ:PAHC) last posted its quarterly earnings data on Wednesday, November 5th. The company reported $0.73 earnings per share for the quarter, beating analysts’ consensus estimates of $0.58 by $0.15. The firm had revenue of $363.89 million for the quarter, compared to analysts’ expectations of $345.44 million. Phibro Animal Health had a return on equity of 36.26% and a net margin of 4.85%.Phibro Animal Health has set its FY 2026 guidance at 2.640-2.810 EPS. On average, analysts expect that Phibro Animal Health Corporation will post 1.95 EPS for the current year.

Phibro Animal Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, December 17th. Stockholders of record on Wednesday, November 26th were given a dividend of $0.12 per share. This represents a $0.48 annualized dividend and a dividend yield of 1.2%. The ex-dividend date was Wednesday, November 26th. Phibro Animal Health’s dividend payout ratio (DPR) is presently 28.92%.

Institutional Investors Weigh In On Phibro Animal Health

Several large investors have recently made changes to their positions in the company. Tudor Investment Corp ET AL increased its stake in Phibro Animal Health by 3.4% in the 3rd quarter. Tudor Investment Corp ET AL now owns 10,184 shares of the company’s stock worth $412,000 after acquiring an additional 338 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Phibro Animal Health by 2.9% in the second quarter. JPMorgan Chase & Co. now owns 13,005 shares of the company’s stock valued at $332,000 after purchasing an additional 363 shares in the last quarter. Farther Finance Advisors LLC increased its position in Phibro Animal Health by 113.2% in the fourth quarter. Farther Finance Advisors LLC now owns 727 shares of the company’s stock worth $27,000 after purchasing an additional 386 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Phibro Animal Health by 4.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,164 shares of the company’s stock valued at $260,000 after purchasing an additional 546 shares in the last quarter. Finally, Prospera Financial Services Inc lifted its position in Phibro Animal Health by 3.6% during the second quarter. Prospera Financial Services Inc now owns 19,910 shares of the company’s stock valued at $508,000 after purchasing an additional 690 shares during the last quarter. 99.34% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have commented on PAHC shares. Weiss Ratings reissued a “buy (b-)” rating on shares of Phibro Animal Health in a report on Monday, December 29th. JPMorgan Chase & Co. lifted their target price on Phibro Animal Health from $45.00 to $50.00 and gave the company an “overweight” rating in a research note on Friday, November 7th. Finally, Zacks Research upgraded Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, December 9th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, two have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $31.40.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.